Microgynon 30/Microgynon 30 ED

Microgynon 30 Levonorgestrel 0.15 mg, ethinylestradiol 0.03 mg. Microgynon 30 ED Levonorgestrel 0.15 mg, ethinylestradiol 0.03 mg plus 7 inactive tab

OC.

Microgynon 30 1 tab daily at about the same time every day, for 21 days starting on the 1st day of menstrual cycle, followed by 7 tab-free days. Microgynon 30 ED 1 tab daily at about the same time every day, starting on the 1st day of menstrual cycle. Take the 1st tab from the red area on the blister pack corresponding to the day of the wk. Follow the direction of the arrow on the blister pack until all tab have been taken.

May be taken with or without food.

Hypersensitivity. Presence or history of DVT, pulmonary embolism, MI, CVA, blood clots in other parts of the body; any blood clotting disorders eg, Protein C deficiency, Protein S deficiency, Leiden Factor V mutation, antithrombin III deficiency or other inherited blood clotting conditions; confirmed increased levels of homocysteine or antiphospholipid Abs; major surgery w/ prolonged immobilisation afterward; angina; transient ischaemic attack; migraine w/ focal neurological symptoms; high risk of blood clots due to conditions eg, diabetes w/ blood vessel damage, severe high BP or severe high or low level of fats in the blood; pancreatitis associated w/ severe hypertriglyceridemia; severe hepatic disease as long as liver function values have not returned to normal; sex-hormone influenced malignancies (eg, of the genital organs or the breasts); benign or malignant liver tumour; undiagnosed vag bleeding. Concomitant use w/ ombitasvir, paritaprevir &/or dasabuvir. Not intended for use in females whose periods have not yet started. Known or suspected pregnancy.

Family history of DVT, pulmonary embolism, MI, CVA, breast cancer or high cholesterol. Smoking. Presence or history of DM, HTN, heart valve disorders or certain heart rhythm disorders, migraine, cancer, hyperhomocysteinaemia; high or low level of fats in the blood. Overwt; any hereditary or acquired conditions that increases risk of blood clots; hypercholesterolaemia or hypertriglyceridaemia; liver disease; gall bladder disease; jaundice &/or pruritus related to cholestasis; Crohn's disease or ulcerative colitis; SLE; haemolytic uraemic syndrome; sickle cell disease; condition that occurred for the 1st time, or worsened during pregnancy or previous use of sex hormones (eg, hearing loss, porphyria, herpes gestationis, Sydenham's chorea); chloasma; hereditary angio-oedema. Inform physician that Microgynon 30/Microgynon 30 ED is being taken before undergoing surgery. Women at risk of prolonged immobilisation (including major surgery, surgery to the legs or pelvis, neurosurgery, major trauma, air travel of >4 hr). May interfere w/ the results of some blood tests. Intolerance to some sugars. Not recommended during lactation.

Acne, nausea, stomach pain, changes in wt, headache (including migraines), mood changes (including depression), breast tenderness or pain, hair loss or hair growth.

Risk of breakthrough bleeding &/or contraceptive failure w/ CYP3A4 inducers. Potential interaction w/ rifampicin, rifabutin; clarithromycin, erythromycin; ketoconazole, griseofulvin; ritonavir, nevirapine; boceprevir, telaprevir, ombitasvir, paritaprevir, dasabuvir; phenytoin, primidone, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate, lamotrigine; cyclosporin; etoricoxib; melatonin; midazolam; theophylline; tizanidine; diltiazem, verapamil; herbal medicines containing St. John's wort; grapefruit juice.

Oral Contraceptives

G03AA07 - levonorgestrel and ethinylestradiol ; Belongs to the class of progestogens and estrogens in fixed combinations. Used as systemic contraceptives.

NP